Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Otsuka Holdings Co., Ltd.
  6. News
  7. Summary
    4578   JP3188220002


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Otsuka : ReCor Medical Launches the Paradise™ Ultrasound Renal Denervation for the Treatment of Hypertension in Europe

10/06/2021 | 12:31pm EST

Treatment Supported by Evidence from Multiple Studies and Renal Denervation Position Paper from the European Society of Hypertension

ReCor Medical, Inc. (“ReCor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the company’s Paradise™ Ultrasound Renal Denervation System (the “Paradise™ System”) is now available for the treatment of uncontrolled hypertension in Germany. The first hospitals performing the procedure commercially are Heart Center Leipzig and Saarland University Hospital, Homburg/Saar.

“Despite the availability of antihypertensive medications, many patients fail to control their hypertension, a dangerous condition that can lead to heart attack and death. Clinical data from the ACHIEVE, RADIOSOUND, RADIANCE-HTN SOLO and TRIO trials show that ultrasound renal denervation with the Paradise System can lower blood pressure and is a new treatment option for physicians to help their selected patients,” said Prof. Felix Mahfoud of Saarland University Hospital and chairman of the Arterial Hypertension Working Group of the German Society of Cardiology (DGK), who served as study investigator for the RADIANCE-HTN SOLO and TRIO trials. “We are pleased to be one of the first hospitals in Europe to offer renal denervation with ultrasound.”

In Leipzig, the first procedure was successfully performed at the Heart Center Leipzig at the University Clinic for Cardiology. There, Prof. Dr. Philipp Lurz and PD Dr. Karl Fengler led the RADIOSOUND trial, and both have participated in the RADIANCE-HTN SOLO and TRIO studies in patients with uncontrolled hypertension.

Paradise ultrasound renal denervation is a device-based, minimally invasive procedure for the treatment of high blood pressure. During the procedure, which usually takes less than an hour, the Paradise catheter is placed in the renal artery. Typically, three doses of ultrasound energy lasting a few seconds are applied to each of the main arteries leading to the kidneys. The ultrasound emissions denervate the renal nerves and cause a reduction in sympathetic nervous system activity, which can result in lower blood pressure.

In September 2021, the European Society of Hypertension published an updated position paper stating that renal denervation “is effective in reducing or interrupting the sympathetic signals to the kidneys and decreasing whole body sympathetic activity.” The society noted that five independent sham-controlled randomized clinical trials—including RADIANCE-HTN SOLO and TRIO—provide “conclusive evidence” that renal denervation can lower ambulatory and office blood pressure both in patients with and without concomitant antihypertensive medication.

“The Paradise System has generated a significant body of clinical evidence in the ACHIEVE, RADIOSOUND, RADIANCE-HTN SOLO and TRIO studies—executed over a number of years in centers across the U.S. and Europe—showing a significant lowering of blood pressure in patients with uncontrolled hypertension,” said ReCor President and CEO Andrew M. Weiss. “The Paradise treatment offers patients and their caregivers a new option to treat their hypertension. We are pleased to make this new therapy available in Germany, and we look forward to introducing the Paradise System to more European countries soon.”

Hypertension is one of the leading contributors to disease burden worldwide, leading to increased cardiovascular morbidity and mortality, impaired quality of life, and increased cost to health systems. Based on meta-analyses of randomized trials using pharmacological treatments, a decrease of 10 mmHg in office systolic blood pressure is estimated to lower the incidence of cardiovascular events by 20%. Despite the broad availability of antihypertensive medications, access to drugs and adherence remain challenging for patients and physicians.

The Paradise System is an investigational device in the United States. ReCor is currently conducting an FDA IDE pivotal study (RADIANCE-II) in patients with uncontrolled hypertension.

About ReCor Medical, Inc.

ReCor Medical, headquartered in Palo Alto, Calif., is a medical technology company focused on transforming the management of hypertension, the leading cardiovascular risk factor in the world. With its Paradise System ReCor has pioneered the minimally invasive use of ultrasound in renal denervation to treat patients with hypertension. The Paradise System is an investigational device in the United States. It is approved for sale in the EU and bears a CE mark. The company has completed two randomized, sham-controlled studies of the Paradise System in patients with both moderate hypertension and those resistant to standard medical therapies. ReCor is currently conducting its FDA IDE pivotal study, RADIANCE-II, and pending successful completion, will submit for PMA approval to market the therapy in the United States.

ReCor Medical is a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd.


About Otsuka Medical Devices Co., Ltd.

Otsuka Medical Devices focuses on the global development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices Co., Ltd. is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a leading global healthcare group listed on the Tokyo Stock Exchange (JP 4578).


ę Business Wire 2021
All news about OTSUKA HOLDINGS CO., LTD.
12/02Unichem Laboratories Gets US FDA Nod for Aripiprazole Tablets
11/19Nikkei rises on chipmakers, energy boost; SoftBank drops
11/11Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending December..
11/11Otsuka Holdings Co., Ltd. Revises Earnings Guidance for the Fiscal Year Ending December..
11/05GSK says anaemia drug shows positive safety profile
11/01GlaxoSmithKline Rebuffs Reports on Potential Bid for Canada's Aurinia Pharmaceuticals
10/29Akebia Says Partner Otsuka Files Initial MAA for Vadadustat with European Medicines Age..
10/06OTSUKA : ReCor Medical Launches the Paradise™ Ultrasound Renal Denervation for the T..
10/06LUPIN : Gets US FDA's Approval for Brexpiprazole Tablets
10/04Sumitomo Dainippon Sells License for Psychiatry and Neurology Compounds to Otsuka for $..
More news
Sales 2021 1 470 B 13 028 M 13 028 M
Net income 2021 158 B 1 399 M 1 399 M
Net cash 2021 271 B 2 401 M 2 401 M
P/E ratio 2021 13,9x
Yield 2021 2,48%
Capitalization 2 209 B 19 533 M 19 571 M
EV / Sales 2021 1,32x
EV / Sales 2022 1,22x
Nbr of Employees 33 151
Free-Float 75,4%
Duration : Period :
Otsuka Holdings Co., Ltd. Technical Analysis Chart | 4578 | JP3188220002 | MarketScreener
Technical analysis trends OTSUKA HOLDINGS CO., LTD.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 12
Last Close Price 4 072,00 JPY
Average target price 4 658,33 JPY
Spread / Average Target 14,4%
EPS Revisions
Managers and Directors
Tatsuo Higuchi President, CEO & Representative Director
Yuko Makino Chief Financial Officer & Director
Ichiro Otsuka Chairman
Yukitakeshi Matsutani Independent Outside Director
Yasushi Sekiguchi Independent Outside Director